Notice concerning proxies received for the Annual General Meeting of NeuroSearch A/S

Announcement                                                                    

Notice concerning proxies received for the Annual General Meeting of NeuroSearch
A/S                                                                             

Pursuant to Section 29 of the Danish Securities Trading Act, NeuroSearch hereby 
informs that the board of directors has received 181 general proxies,           
representing a total of nominal DKK 31,900,660 of the issued share capital,     
corresponding to 10.3% of the company's total share capital and 14.1% of the    
voting rights for the Annual General Meeting to be held on 30 April 2008.       

The above proxies will no not be valid after the Annual General Meeting (or a   
possible subsequent Extraordinary General Meeting), and therefore NeuroSearch   
will not send out a separate announcement regarding this matter.                

Following the Annual General Meeting (or a possible subsequent Extraordinary    
General Meeting) NeuroSearch will possess 0% of the voting rights.              



Asger Aamund                                                                    
Chairman of the board of directors                                              



Contact persons:                                                                
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118               
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,  
telephone: +45 4460 8212 or +45 4017 5103                                       




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III), tesofensine in obesity (Phase III in          
preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership
with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with    
Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in
bipolar disorder (Phase I), ABT-107 as well as ABT-560 for the treatment of     
various CNS diseases - both (Phase I) in collaboration with Abbott, NSD-644 in  
pain (Phase I) in partnership with GSK, ACR343 in Parkinson's disease (Phase I) 
and NSD-788 in anxiety/depression (Phase I). In addition, NeuroSearch has a     
broad portfolio of preclinical drug candidates and holds equity interests in    
several biotech companies.